A recent review highlights how the Mediterranean diet can reduce inflammation and improve outcomes for chronic skin ...

The two simultaneous Incyte trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.

Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed ...

Steven Daniel Daveluy, MD, FAAD, discussed how artificial intelligence (AI) can leverage extensive patient data and guide dermatologists to improve early diagnosis and treatment of rare dermatological ...

Newly released data from the phase 3 STOP-HS clinical trial program reveal positive results in hidradenitis suppurativa from ...

Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...

Incyte’s quest for its next big thing ended in disappointment—and a stock tumble—this past week. Unfortunately, the problems go well beyond the recent selloff or the latest trial, as long-term ...

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients with Hidradenitis ...

Povorcitinib is an oral Janus kinase 1 selective inhibitor that works to reduce the overactive inflammatory signaling pathway seen in HS.

It’s not known whether Cosentyx (secukinumab) is safe to receive while pregnant or breastfeeding. Certain factors may ...

MoonLake Immunotherapeutics (MLTX) stock gains as RBC Capital Markets starts with outperform rating, citing $2B+ sales ...